ATS Medical announced first Commercial Implants in the United States





ATS Medical, Inc., manufacturer and marketer of state-of-the-art cardiac surgery products and services, announced that the first three commercial implants of the ATS 3f(R) Aortic Bioprosthesis were completed by Dr. Allan Stewart, Director, Aortic urgery Program at Columbia University Medical Center in New York.

"The ATS 3f Aortic Bioprosthesis is the only tissue valve that preserves the sinuses and restores native valve stress distribution and physiologic flow to the entire aortic root," commented Dr. Stewart. "All three patients achieved postoperative aortic function that is nearly indistinguishable from a healthy native aortic valve. All three patients have been discharged with an excellent prognosis and remarkably low pressure gradients of 4, 2, and 0 mm Hg."

Mr. Dale, President and Chief Executive Officer of ATS Medical, The commercial launch of our first tissue valve in the U.S. is an important milestone for ATS Medical. The tissue valve market presents the largest market opportunity of our current products and will importantly provide ATS Medical the leverage it needs to sustain high growth and enhanced profitability in the future. We are grateful to Dr. Stewart for his commitment to science and excellent patient care.

The tubular design of the ATS 3f Aortic Bioprosthesis maintains the continuity of the annulus and the sino-tubular junction. No other valve mimics the native valve in this manner. By maintaining this continuity, the ATS 3f Aortic Bioprosthesis preserves the aortic sinuses and restores native valve stress distribution and physiologic blood flow. This elegant design provides surgeons and patients with a potentially more durable solution to aortic valve replacement.